Paras Satadeve
YOU?
Author Swipe
View article: Evaluation of response assessment in chronic lymphocytic leukaemia using measurable residual disease by flow cytometry: Prospective observational study.
Evaluation of response assessment in chronic lymphocytic leukaemia using measurable residual disease by flow cytometry: Prospective observational study. Open
Background : Measurable residual disease (MRD) status has recently emerged to evaluate treatment efficacy, predict long-term outcomes, and inform therapeutic strategies in Chronic lymphocytic leukaemia (CLL). By analysing treatment outcome…
View article: Comparison of consecutive versus alternate day schedules of high-dose cytarabine consolidation chemotherapy in Acute Myeloid Leukemia: Single-center randomized controlled trial from India
Comparison of consecutive versus alternate day schedules of high-dose cytarabine consolidation chemotherapy in Acute Myeloid Leukemia: Single-center randomized controlled trial from India Open
INTRODUCTION The treatment strategy of patients with Acute myeloid leukaemia (AML) includes induction chemotherapy which is to achieve remission and consolidation. High-dose cytarabine (HiDAC) is considered the standard consolidation thera…
View article: Marked leukemoid reaction preceded the onset of meningitis: A case report
Marked leukemoid reaction preceded the onset of meningitis: A case report Open
The leukemoid reaction is defined as leukocytosis >50,000/μL, whereas a white blood cell count of more than 11 × 10 9 leukocytes/L is called leukocytosis. The etiology of leukemoid reactions ranges from benign to hematologic neoplasms and …
View article: t (1;12) (p31; q13) cytogenetic abnormality in a patient of idiopathic hypereosinophilic syndrome: A case report
t (1;12) (p31; q13) cytogenetic abnormality in a patient of idiopathic hypereosinophilic syndrome: A case report Open
Hypereosinophic syndrome (HES) is a heterogenous group of disorders comprising various etiology. Idiopathic HES is diagnosis of exclusion after morphological, radiological and molecular investigations. Cytogenetic analysis remains an impor…
View article: Treatment Outcomes in Acute Promyelocytic Leukemia Patients Using a Uniform ATRA + ATO Consolidation Therapy Regimen across All Risk Groups: A Single Centre Study from India
Treatment Outcomes in Acute Promyelocytic Leukemia Patients Using a Uniform ATRA + ATO Consolidation Therapy Regimen across All Risk Groups: A Single Centre Study from India Open
INTRODUCTION Acute Promyelocytic Leukemia (APL) is a particularly aggressive subtype of acute myeloid leukemia associated with high risk of early mortality due to coagulopathy & bleeding. The current standard induction therapy for APL comp…
View article: Real-World Data of Molecular Response Using Different Dosage of Upfront Generic Dasatinib in Chronic Phase Chronic Myeloid Leukemia: Single-Center Experience from India
Real-World Data of Molecular Response Using Different Dosage of Upfront Generic Dasatinib in Chronic Phase Chronic Myeloid Leukemia: Single-Center Experience from India Open
Introduction The 2nd generation tyrosine kinase inhibitor (TKI) agent dasatinib is approved for upfront therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP) patients. The recommended dasatinib dose of 100mg/day is fre…
View article: Real-World Experience with Generic Venetoclax Plus Hypomethylating Agent Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia Patients in Resource-Limited Setting: A Single-Center Study from India
Real-World Experience with Generic Venetoclax Plus Hypomethylating Agent Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia Patients in Resource-Limited Setting: A Single-Center Study from India Open
INTRODUCTION The standard induction therapy for acute myeloid leukemia (AML) is the intensive 3+7 regimen. However, a significant proportion of newly diagnosed AML patients are often ineligible for 3+7 induction therapy and are being treat…
View article: A Study of Cytokine patterns of T helper type 1 cytokine (IL-2), T helper type 2 cytokine (IL-6) and Regulatory cytokine (IL-10) in Chronic Lymphocytic Leukemia (CLL) – A Real World Data at a tertiary care center
A Study of Cytokine patterns of T helper type 1 cytokine (IL-2), T helper type 2 cytokine (IL-6) and Regulatory cytokine (IL-10) in Chronic Lymphocytic Leukemia (CLL) – A Real World Data at a tertiary care center Open
Chronic lymphocytic leukemia (CLL) remains a challenging disease to manage due to its heterogeneous nature and the lack of clarity regarding prognostic markers. This study aimed to clarify cytokine behavior in different stages (Binet and M…
View article: P400: COMPARISON OF MORPHOLOGICAL & MRD RESPONSE WITH DEXAMETHASONE VERSUS PREDNISOLONE IN BFM 2009 INDUCTION THERAPY IN PEDIATRIC AND AYA ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER STUDY FROM INDIA
P400: COMPARISON OF MORPHOLOGICAL & MRD RESPONSE WITH DEXAMETHASONE VERSUS PREDNISOLONE IN BFM 2009 INDUCTION THERAPY IN PEDIATRIC AND AYA ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER STUDY FROM INDIA Open
Background: Acute lymphoblastic leukemia (ALL) is the commonest cancer in children. With the evolution of MRD adapted intensive treatment regimens in children & AYA with ALL, survival rates have improved significantly. Multiple studies sho…
View article: PB1906: HYPOMETHYLATING AGENT PLUS LOW DOSE VENETOCLAX – A CHEMOTHERAPY-FREE INDUCTION OF ACUTE MYELOID LEUKEMIA TO ACHIEVE COMPLETE REMISSION IN PATIENTS UNFIT FOR CHEMOTHERAPY
PB1906: HYPOMETHYLATING AGENT PLUS LOW DOSE VENETOCLAX – A CHEMOTHERAPY-FREE INDUCTION OF ACUTE MYELOID LEUKEMIA TO ACHIEVE COMPLETE REMISSION IN PATIENTS UNFIT FOR CHEMOTHERAPY Open
Topic: 4. Acute myeloid leukemia - Clinical Background: Breakthrough in managing acute myeloid leukemia(AML) came in 1973 after the results of “3 + 7” combination induction regimen (daunorubicin and cytosine arabinoside) was published. For…